Dr. Lanocha has more than 25 years of experience in neuromodulation therapies for treatment-resistant depression, including both TMS and ECT. He was among the first physicians in the country to begin offering TMS when it was approved by the FDA in 2008. He has lectured widely about TMS. His research activities have focused on long-term clinical outcomes following TMS treatment for major depression.
Dr. Bermudes is Medical Director at TMS Health Solutions. He is the current president of the Clinical TMS Society, a professional association dedicated to optimizing clinical practice, awareness, and affordability of Transcranial Magnetic Stimulation therapy. He has consulted with TMS industry leaders to help formulate insurance coverage policies for TMS therapy.
Dr. Holtzheimer is the Director of the Mood Disorders Service at Dartmouth Hitchcock Medical Center, where his research is focused on the neurobiology and treatment of mood disorders, primarily treatment-resistant depression. He has been an investigator in several clinical trials of novel treatments, including TMS and deep brain stimulation, as well as numerous studies investigating the structural and functional neuroanatomy of mood disorders.
Dr. George is one of the world’s leading authorities on TMS. From his pioneering work at NIH, to the publication of one of the very first studies of TMS in the treatment of depression, to the pivotal trial leading to FDA approval of TMS and the subsequent NIMH replication trial, he is rightfully regarded as one of the “fathers “ of TMS. As editor of the Journal of Brain Stimulation, he helped forge a whole new specialty of neuropsychiatric medicine. In his capacity as Director of the Brain Stimulation Laboratory at the Medical University of South Carolina, his ongoing research is now focusing on TMS in the treatment of stroke and other neurological disorders.
Dr. McClintock is Associate Professor in the Department of Psychiatry at UT Southwestern Medical Center, and is Adjunct Associate Professor in the Department of Psychiatry and Behavioral Sciences at Duke University School of Medicine. His clinical research has focused on neuropsychological evaluation and clinical outcomes assessment of patients undergoing TMS and other neuromodulation treatments for major depression and other neuropsychiatric disorders.
Previously at Rush University and now the Director of TMS at Linden Oaks, Dr. Janicak has long been regarded as a leading expert in psychopharmacology and neuromodulation, including both TMS and ECT. He has written extensively on the long-term safety and efficacy of TMS in treatment resistant-depression, including the pivotal study leading to FDA approval of TMS.
Dr. Cook is Director of the UCLA Depression Research and Clinic Program at the Semel Institute and Founding Chief of the TMS Treatment Service in the UCLA Department of Psychiatry. His research focuses on improving existing treatments for depression and developing new treatments for depression and related disorders. As both a biomedical engineer and a physician, he is at the forefront of the rapidly expanding field of neuromodulation and has published landmark studies of several novel neuromodulation therapies.
Dr. Demitrack has extensive experience in the treatment of mood disorders. In his role as Chief Medical Officer of Neuronetics, Inc., his research has focused on the use of TMS for treatment-resistant major depression. In addition to his numerous publications regarding TMS in the treatment of depression, he has written extensively on the neuroendocrinology of mood disorders.
Dr. Williams is an Instructor of Psychiatry at Stanford University, where his research program is focused on the development of new therapeutic approaches for treatment-resistant depression. He has been an investigator in several clinical trials of novel treatments, including intravenous ketamine and epidural cortical stimulation. Dr. Williams has been recently funded to complete several studies investigating the functional neuroanatomy of mood disorders with advanced imaging techniques. He is currently developing new forms of rTMS treatments such as accelerated theta-burst stimulation as well as biomarkers to measure the changes induced by rTMS such as resting-state functional connectivity MRI.